
Novocure (NVCR) announced that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy concomitant with
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| NVCR | NovoCure | 11.83 | 0.51 | 4.51% |
| Name | Price | % Change | |
|---|---|---|---|
| $11.83 | +4.51% |

Novocure (NVCR) announced that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields therapy concomitant with

Ladenburg raised the firm’s price target on Novocure (NVCR) to $31 from $27 and keeps a Buy rating on the shares following the FDA not approvable letter for Optune Mya.

NovoCure ( ($NVCR) ) has provided an update. On November 9, 2026, Novocure received a Not Approvable Letter from the U.S. Food and Drug Administration for its application seeking approval

Novocure (NVCR) announced that it has received a Not Approvable Letter from the U.S. Food and Drug Administration, FDA, in response to its Premarket Approval, PMA, application for Optune Mya

NovoCure Ltd. (($NVCR)) has held its Q3 earnings call. Read on for the main highlights of the call. NovoCure’s latest earnings call carried a strongly positive tone, supported by record

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $20 from $23 and keeps an Outperform rating on the shares. Published first on TheFly –

Wedbush notes that active patients on Novocure’s (NVCR) Optune Pax declined to 276 in Q3 from 285 in Q2, reporting that management cited disruption from the introduction of Revolution Medicines’

Reports Q3 revenue $193.4M, consensus $182.23M. “Novocure’s (NVCR) strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in

Consensus $726.12M. Adjusted EBITDA: $24M – $34M, previous: $0M – $15M. This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua

Novocure (NVCR) announced that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields therapy with chemotherapy
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $1.38B | $-0.21 | $189.80M | 0.49 | -11.16 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.